Literature DB >> 9305865

Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin.

S D Desai1, L F Liu, D Vazquez-Abad, P D'Arpa.   

Abstract

Topoisomerase I (TOP1) relaxes superhelical DNA through a breakage/rejoining reaction in which the active site tyrosine links covalently to a 3' phosphate at the break site as a transient intermediate. The antitumor drug camptothecin (CPT) and its analogs inhibit the rejoining step of the breakage/rejoining reaction, which traps the enzyme in covalent linkage with DNA (the cleavable complex). Little is known about the fate of cellular TOP1 trapped in the cleavable complex. We have analyzed TOP1 in mammalian cell lines treated with CPT. When CPT-treated cells were lysed with either SDS or alkali and analyzed by Western blotting, greater than 90% of the TOP1 was linked to DNA. Nuclease treatment of the cell lysate to remove the covalently linked DNA from TOP1 revealed a distinct ladder of higher molecular weight bands having properties indicative of multi-ubiquitin (Ub) conjugates of TOP1. Approximately 5-10% of TOP1 was present as these conjugates within minutes of CPT treatment. Consistent with ubiquitination, TOP1 was not modified in ts85 cells at the restrictive temperature for its thermolabile ubiquitin-activating enzyme (E1). Because conjugation with ubiquitin can mark proteins for destruction by the 26S proteasome, we analyzed TOP1 protein levels during prolonged CPT treatment. TOP1 protein levels were reduced to about 25% during CPT treatments of 2-4 h resulting from increased destruction, with the half-life dropping from 10-16 h down to 1-2 h. The destruction of TOP1, like the formation of Ub-TOP1 conjugates, was not observed in ts85 cells at the restrictive temperature. The destruction of TOP1 was also prevented in cells treated with MG-132 and lactacystin, specific inhibitors of the 26S proteasome. Finally, the multi-Ub conjugates of TOP1 were observed whether or not aphidicolin was included in cotreatment with CPT, indicating that replication fork activity was not involved in making TOP1 a substrate for ubiquitination. These results demonstrate that independent of DNA replication, the TOP1 cleavable complex is ubiquitinated and destroyed in cells treated with antitumor drugs that block the religation step of the TOP1 reaction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9305865     DOI: 10.1074/jbc.272.39.24159

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  76 in total

1.  A human topoisomerase I cleavage complex is recognized by an additional human topisomerase I molecule in vitro.

Authors:  K Søe; G Dianov; H P Nasheuer; V A Bohr; F Grosse; T Stevnsner
Journal:  Nucleic Acids Res       Date:  2001-08-01       Impact factor: 16.971

2.  The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway.

Authors:  Hai Xiao; Yong Mao; Shyamal D Desai; Nai Zhou; Chun-Yuan Ting; Jaulang Hwang; Leroy F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

3.  A novel method of eliminating non-neuronal proliferating cells from cultures of mouse dorsal root ganglia.

Authors:  Parker L Andersen; J Ronald Doucette; Adil J Nazarali
Journal:  Cell Mol Neurobiol       Date:  2003-04       Impact factor: 5.046

Review 4.  DNA-protein crosslinks from environmental exposure: Mechanisms of formation and repair.

Authors:  Yusuke Kojima; Yuichi J Machida
Journal:  Environ Mol Mutagen       Date:  2020-07-09       Impact factor: 3.216

Review 5.  Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Authors:  Fengzhi Li; Tao Jiang; Qingyong Li; Xiang Ling
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

6.  Ubiquitin-family modifications of topoisomerase I in camptothecin-treated human breast cancer cells.

Authors:  Ragu Kanagasabai; Shujun Liu; Samir Salama; Edith F Yamasaki; Liwen Zhang; Kari B Greenchurch; Robert M Snapka
Journal:  Biochemistry       Date:  2009-04-14       Impact factor: 3.162

Review 7.  SUMO modification of DNA topoisomerase II: trying to get a CENse of it all.

Authors:  Ming-Ta Lee; Jeff Bachant
Journal:  DNA Repair (Amst)       Date:  2009-02-20

8.  Transcription-dependent degradation of topoisomerase I-DNA covalent complexes.

Authors:  Shyamal D Desai; Hui Zhang; Alexandra Rodriguez-Bauman; Jin-Ming Yang; Xiaohua Wu; Murugesan K Gounder; Eric H Rubin; Leroy F Liu
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

9.  ISG15 as a novel tumor biomarker for drug sensitivity.

Authors:  Shyamal D Desai; Laurence M Wood; Yu-Chen Tsai; Tao-Shih Hsieh; Jeffrey R Marks; Georgia L Scott; Beppino C Giovanella; Leroy F Liu
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

10.  Proteasome inhibition suppresses DNA-dependent protein kinase activation caused by camptothecin.

Authors:  Ryo Sakasai; Hirobumi Teraoka; Randal S Tibbetts
Journal:  DNA Repair (Amst)       Date:  2009-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.